Immediately thereafter, Scandion Oncology’s Chairman of the Board, Dr. Peter Høngaard Andersen bought an additional 6000 shares in Scandion Oncology resulting in a total holding on 37,839 shares – corresponding to a monetary value of approximately 1.65 million SEK – a strong show of faith and confidence in the company’s vision, technology and team.

CRDF: Get the latest Cardiff Oncology stock price and detailed information including CRDF news, historical charts and realtime prices. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this

2021-3-10 · Learn about SCOL (XSTO) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial … Immediately thereafter, Scandion Oncology’s Chairman of the Board, Dr. Peter Høngaard Andersen bought an additional 6000 shares in Scandion Oncology resulting in a total holding on 37,839 shares – corresponding to a monetary value of approximately 1.65 … Scandion Oncology A/S options quotes data for sells and puts, including SCOL.SE last price, change and volume. 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares.

Du kan återkalla samtycket när som helst genom skriftligt meddelande till Bolaget. Certified Adviser. Scandion Oncology. What to expect in 2019 (including the stock price). What the Investment Ownership Cadent Therapeutics / Scandion Oncology. 60. Fair value.

CSO Nils Brünner will retire from Scandion Oncology A/S. 19.3.2021 12.20 · Cision. Scandion Oncology A/S: Scandion Oncology appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations. 5.3.2021 11.33 · Nyhetsbyrån Direkt.

With a market capitalization of kr939m, Scandion Oncology is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Scandion Oncology.

NASDAQ. 13,698.38. FTSE 100.

Access detailed information about the Scandion Oncology A/S (SCOLG) Share including Price, Charts, Technical Analysis, Historical data, Scandion Oncology Reports and more.

556736-8195 MIC Code XSAT | FI no. 35373 Klarabergsviadukten 63, 9th floor 101 23 Stockholm Immediately thereafter, Scandion Oncology’s Chairman of the Board, Dr. Peter Høngaard Andersen bought an additional 6000 shares in Scandion Oncology resulting in a total holding on 37,839 shares – corresponding to a monetary value of approximately 1.65 million SEK – a strong show of faith and confidence in the company’s vision, technology and team. Bolagspresentation med Scandion Oncology. Bolaget presenteras av vd Bo Rode Hansen 2021-04-12 · Scandion Oncology was formed in 2017 through a spin-out of certain oncology assets from Saniona. At the time of the spin-out, Saniona owned a 51% stake in Scandion Oncology. 2020-06-16 10:30:54 Scandion Oncology A/S: Scandion Oncology has received a Eurostars grant of 800,000 EUR, shared with Erasmus Medical Centre, Rotterdam and 2cureX AB, for evaluating SCO-101 against antiestrogen resistance in breast cancer +12,32% | 13,5 MSEK Bakgrund Scandion Oncology är ett bioteknikbolag grundat 2017 i syfte att angripa en av de största utmaningarna inom modern onkologi – behandling av cancer som innehåller läkemedelsresistenta cellkloner eller som har utvecklat resistens mot ett tidigare givet cancerläkemedel.

mässan eget Index, %, Senast, Tid. OMX Stockholm PI, +1,46%, 921,13, 17:30. OMX Stockholm 30 Index, +1,67%, 2 280,50, 17:29.
Deflation inflation problems

Scandion Oncology, The Cancer Drug Resistance Company, is pleased to announce that Dr. Maj Hedtjärn is appointed Chief Operating Officer (COO) and Head of R&D Operations in the company. Dr. Maj Hedtjärn will be leading the professional execution of Scandion Oncology's pipeline towards upcoming value inflection points starting with our read Scandion Oncology A/S Annual stock financials by MarketWatch.

Shares in Scandion Oncology A/s ( AKT:SCOL) are currently trading close to a 52 week high, with the share price up by around 29.3% to 72 over the past week.
God sed juridik

dhl express uppsala
besikta bilprovning karlstad
tesla lastebil norge
utdelning nokia 2021
logistiskt omöjligt
fn jobber i norge
nel noddings theory

View live SCANDION ONCOLOGY A/S chart to track its stock's price action. Find market predictions, SCOL financials and market news.

Med “Spotlight” avses Spotlight Stock Market. FINANSIELL RÅDGIVARE OCH EMISSIONSINSTITUT I samband med nyemissionen som beskrivs i detta memorandum är Sedermera Fondkommission finansiell Scandion Oncology was listed on Spotlight Stock Market November 8th 2018.They develop drugs that target anti-cancer drug resistance to improve patient outcome Genevant Sciences CEO joins board at Danish oncology firm. Biotech company Scandion Oncology expands its board of directors, adding Bo Rode Hansen, who left an executive position at Roche in 2018 to become chief science officer and since CEO of a US start-up in Boston.

Smaaken waffles beaverton
yr strømstad

Peter Høngaard Andersen explains, and he continues; “The current massive sale of shares has put our share price under pressure and I want to

In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Scandion Oncology's cash burn of kr.7.6m is about 1.7% of its kr.452m market capitalisation.